BioSpace News Archive

Masimo O3 ® Regional Oximetry Receives FDA Clearance for Somatic Applications and Measurement of Relative Changes in Cerebral Hemoglobin IRVINE, Calif.--( BUSINESS WIRE )-- Masimo (NASDAQ: MASI) today announced that O3 ® Regional Oximetry has received FDA clearance for expanded use in monitoring somatic tissue oxygenation saturation in all patient populations and monitoring relative changes in hemoglobin, oxyhemoglobin, and deoxyhemoglobin in adult brain

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling $44 million, and has added approximately $3 million to its existing contract (HHSN272201300017C), to support the development of galidesivir. The additional funds under these performance-base

Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented its newly developed HBICE TM (HCAb Based Immune Cell Engager) platform and its ability to generate fast and reliable next-generation bispecific antibodies for immunotherapies at the 16th PEGS Boston Summit. The poster will

Initiating VYEPTI™ (eptinezumab-jjmr) migraine prevention during a migraine attack demonstrated positive results in the RELIEF study

WAT Medical Enterprise has been supporting the world’s cancer research. They donated part of the profits from selling EmeTerm on Amazon to the M.D. Anderson Cancer Center to support the development of global cancer. After making the donation in August 2019 , WAT Medical Enterprise will continue to support the cause of M.D. Anderso

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that the FDA has allowed two Phase 2 studies to begin testing ebselen (SPI-1005) in COVID-19 patients. SPI is developing SPI-1005, a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication. 120 adults with moderate or severe disease will

Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced today the appointment of Robb Lawrence as Vice President of Commercial Strategy. In this senior leadership role, Lawrence will lead the design and development of strategic solutions that optimize patient access and outcomes by navigating the

Ellipsis Health, pioneer of the first commercial-grade voice-based vital signs to quantify and manage depression and anxiety symptoms at scale, has announced the general availability of the Rising Higher mobile app.

Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center are among the first in the world to participate in a clinical trial to evaluate a new intra-cardiac echocardiography catheter. Andrea Natale , M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of

Kalderos, the creator of the country’s first Drug Discount Management platform, announced today the addition of Mark Niemaszek, recently retired vice president of commercial operations at Astellas Pharma US, to its board of directors.